Inflammatory and Genetic Predictors of Cognitive and Emotional Recovery After Critical Illness (CORE-ICU)
Unraveling the Role of Cognitive Reserve, Inflammatory Phenotype and Genetic Vulnerability on Cognitive and Emotional Recovery After Critical Illness
Survivors of critical illness frequently develop persistent cognitive and emotional impairments, known as post-intensive care syndrome (PICS), which substantially impact quality of life and long-term recovery. While prior research has mainly focused on identifying risk factors, the mechanisms underlying resilience to these sequelae remain poorly understood. Emerging evidence suggests that biological factors, including inflammatory responses and genetic vulnerability, together with cognitive reserve, may play a key role in shaping recovery trajectories.
The aim of this multicenter, prospective observational study is to investigate how cognitive reserve, inflammatory phenotype, and genetic profiles interact to influence cognitive and emotional recovery after critical illness. Adult patients will be recruited at Intensive Care Unit (ICU) admission across two centers in Spain. Clinical and sociodemographic data will be collected during the ICU stay, and biological samples obtained early after admission will undergo transcriptomic and genetic analyses. Cognitive and emotional outcomes will be assessed at hospital discharge and at 3 and 12 months post-discharge using standardised neuropsychological and telemedicine-based evaluations.
By integrating clinical, biological, and cognitive data, this study seeks to identify recovery phenotypes and resilience mechanisms in PICS. The results may contribute to improved risk stratification, inform personalized interventions, and support the development of future strategies aimed at reducing the long-term burden of critical illness.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Sol Fernández-Gonzalo, PhD
- Número de telefone: +34937236673
- E-mail: msfernandez@tauli.cat
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Adult patients (≥18 years)
- Admitted to a medical-surgical ICU or cardiac ICU for causes of critical illness (e.g., acute pulmonary oedema, myocardial infarction, aortic dissection)
- With or without the need for invasive mechanical ventilation
- With an expected ICU stay of ≥48 hours
- Resident in Catalonia or the Principality of Asturias
- Who speak Catalan and/or Spanish
- Who are able to provide informed consent personally or through an authorised representative (e.g., a family member)
Exclusion Criteria:
- Non-authorisation by the patient and/or relatives for inclusion in the study
- Patients admitted to a neurocritical ICU
- History of severe neurological disease (including dementia or focal brain injury with functional and cognitive impairment) prior to ICU admission
- History of severe psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder)
- Intellectual disability (IQ <80) or other neurodevelopmental disorders, such as autism spectrum disorder
- Patients who develop secondary complications (e.g., infections, stroke, traumatic brain injury, or other non-transient acquired brain injury) after ICU discharge that may compromise the results of emotional and neuropsychological evaluations during the recovery phase
- Moderate to severe cognitive impairment (Short-IQCODE >57) preventing independent participation in telemedicine or face-to-face follow-up
- Readmission to the ICU within 12 months after ICU discharge
- Language barrier (non-Spanish- and/or non-Catalan-speaking patients)
- Patients with a life expectancy <1 year or not eligible for active treatment measures
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Critically ill patients (Parc Taulí Hospital)
|
|
Critically ill patients (Hospital Universitario Central de Asturias)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognitive Reserve
Prazo: Within 24-48 hours after ICU discharge
|
Rami- Cognitive Reserve Questionnaire Score range: 0-25 Cognitive Reserve levels: Low: 0-6 Medium-low: 7-9 Medium-high: 10-14 |
Within 24-48 hours after ICU discharge
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Inflammatory phenotypes
Prazo: Within 24-48 hours of ICU admission
|
To characterize inflammatory and anti-inflammatory response phenotypes using transcriptomic and biomarker data
|
Within 24-48 hours of ICU admission
|
|
APOE genotype
Prazo: Within 24-48 hours of ICU admission
|
To characterize pathological aging mechanisims with APOE genotype
|
Within 24-48 hours of ICU admission
|
|
Level of consciousness
Prazo: During ICU stay (up to 28 days)
|
Measured using the Richmond Sedation-Agitation Scale (RASS) Score range: from -5 (unarousable) to +5 (agitated)
|
During ICU stay (up to 28 days)
|
|
Illness severity
Prazo: During ICU stay (up to 28 days)
|
Assessed using the Sequential Organ Failure Assessment (SOFA) questionnaire Score range: 0-24; 0-6: Mild organ dysfunction 7-9: Moderate severity 10-12: Significant organ dysfunction 13+: Severe illness with substantially increased mortality risk |
During ICU stay (up to 28 days)
|
|
Comorbidity burden
Prazo: During ICU stay (up to 28 days)
|
Measured using the Charlson Comorbidity Index (CCI) 0-1 point: Low comorbidity (absence of comorbidities or only very mild diseases). 2-3 points: Moderate to low comorbidity. 4 points or more: Severe comorbidity or high risk. |
During ICU stay (up to 28 days)
|
|
Frailty level
Prazo: During ICU stay (up to 28 days)
|
Assessed using the Rockwood Clinical Frailty Scale (CFS) Score range from 0 to 9; 1-3: Fit / Non-frail 4: Vulnerable / Very mild frailty 5: Mild frailty 6: Moderate frailty 7-8: Severe to very severe frailty 9: Terminal illness |
During ICU stay (up to 28 days)
|
|
Presence of delirium
Prazo: During ICU stay (up to 28 days)
|
Assessed using the Confusion Assessment Method for the ICU (CAM-ICU) Recorded as Yes/No
|
During ICU stay (up to 28 days)
|
|
Need and type of mechanical ventilation
Prazo: During ICU stay (up to 28 days)
|
Categorised as:
|
During ICU stay (up to 28 days)
|
|
Sedation treatment
Prazo: During ICU stay (up to 28 days)
|
Type of sedative agents administered:
|
During ICU stay (up to 28 days)
|
|
Benzodiazepine use
Prazo: During ICU stay (up to 28 days)
|
Recorded as Yes/No
|
During ICU stay (up to 28 days)
|
|
Global cognitive function (MoCA)
Prazo: At 3 months and 12 months after ICU discharge
|
Assessed using the Montreal Cognitive Assessment (MoCA) Score range: 0-30 Interpretation: 26-30 Normal cognitive function 18-25 Mild cognitive impairment (possible) 10-17 Moderate cognitive impairment <10 Severe cognitive impairment |
At 3 months and 12 months after ICU discharge
|
|
Attention and working memory
Prazo: At 3 months and 12 months after ICU discharge
|
Assessed using Digit Span Forward and Backward (WAIS-IV); Scaled score range: 1-19.
Higher scores indicate better performance; scores <8 suggest impairment.
|
At 3 months and 12 months after ICU discharge
|
|
Verbal memory
Prazo: At 3 months and 12 months after ICU discharge
|
Assessed using the Rey Auditory Verbal Learning Test (RAVLT); Total score range recall varies (typically 0-75).
Higher scores indicate better verbal learning and memory.
|
At 3 months and 12 months after ICU discharge
|
|
Processing speed
Prazo: At 3 months and 12 months after ICU discharge
|
|
At 3 months and 12 months after ICU discharge
|
|
Cognitive flexibility
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Trail Making Test Part B (TMT-B); measured in seconds.
Lower completion time indicates better performance.
|
At 3 and 12 months after ICU discharge
|
|
Inhibitory control
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Stroop Colour and Word Test.
Higher scores indicate greater impairment in inhibitory control.
|
At 3 and 12 months after ICU discharge
|
|
Verbal fluency
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Phonetic Fluency (FAS) Test; measured as the number of words generated.
Higher scores indicate better verbal fluency.
|
At 3 and 12 months after ICU discharge
|
|
Depression
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Patient Health Questionnaire-9 (PHQ-9). Score range 0-27; 0-4: None 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe |
At 3 and 12 months after ICU discharge
|
|
Anxiety
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Generalized Anxiety Disorder-7 (GAD-7). Score range 0-21; 0-4: Minimal 5-9: Mild 10-14: Moderate 15-21: Severe |
At 3 and 12 months after ICU discharge
|
|
Post-traumatic stress disorder
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Treatment-Outcome Posttraumatic Stress Disorder Scale (TOP-8) Score range 0-32.
Higher scores indicate greater PTSD symptom severity.
|
At 3 and 12 months after ICU discharge
|
|
Perceived cognitive deficits
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Perceived Deficits Questionnaire (PDQ-D5).
Score range 0-20.
Higher scores indicate greater perceived cognitive impairment.
|
At 3 and 12 months after ICU discharge
|
|
Fatigue
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the FACIT Fatigue Scale (FACIT-F).
Score range 0-52.
Lower scores indicate greater fatigue, while higher scores indicate less fatigue.
|
At 3 and 12 months after ICU discharge
|
|
Pain
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Visual Analogue Scale (VAS-10). Score range 0-10; 0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe |
At 3 and 12 months after ICU discharge
|
|
Dyspnea
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Visual Analogue Scale (VAS-10). Score range 0-10; 0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe |
At 3 and 12 months after ICU discharge
|
|
Sleep quality
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Pittsburgh Sleep Quality Index (PSQI).
Score range 0-21.
Scores >5 indicate poor sleep quality.
|
At 3 and 12 months after ICU discharge
|
|
Resilience (post-traumatic growth)
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the Posttraumatic Growth Inventory (PTGI).
Score range 0-105.
Higher scores indicate greater post-traumatic growth.
|
At 3 and 12 months after ICU discharge
|
|
Quality of life
Prazo: At 3 and 12 months after ICU discharge
|
Assessed using the 12-Item Short Form Health Survey (SF-12).
Score range 0-100.
Higher scores indicate better health-related quality of life.
|
At 3 and 12 months after ICU discharge
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PID2024-160948OA-I00
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data generated will be deposited in recognized open access repositories, accompanied by clear and standardized metadata, which will facilitate its discovery and reuse by other researchers (Institutional reference repository: CORA https://dataverse.csuc.cat/).
These measures not only ensure responsible treatment of data, but also guarantee their reuse and control
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .